AGER

AGER genetic polymorphisms increase risks of breast and lung cancers

N. C. Yin, Lang, X. P., Wang, X. D., and Liu, W., AGER genetic polymorphisms increase risks of breast and lung cancers, vol. 14, pp. 17776-17787, 2015.

We evaluated the associations between three common polymorphisms in the AGER gene and the risks of breast (BC) and lung (LC) cancer using meta-analysis. A systematic electronic search of the literature was conducted to identify all potential correlation studies in Embase, Web of Science, Cochrane Library, CINAHL, PubMed, CISCOM, China BioMedicine (CBM), and China National Knowledge Infrastructure (CNKI) databases.

The functional polymorphisms -429T>C and -374T>A of the RAGE gene promoter are not associated with gestational diabetes in Euro-Brazilians

I. C. R. Santos, Daga, D. R., Frigeri, H. R., Réa, R. R., Almeida, A. C. R., Souza, E. M., Pedrosa, F. O., Fadel-Picheth, C. M. T., and Picheth, G., The functional polymorphisms -429T>C and -374T>A of the RAGE gene promoter are not associated with gestational diabetes in Euro-Brazilians, vol. 9. pp. 1130-1135, 2010.

The receptor for advanced glycation end products (RAGE or AGER) is a multiligand member of the immunoglobulin superfamily. RAGE is expressed in several tissues, including human myometrium, chorionic villi and placenta. Advanced glycation end products are the best studied ligands of RAGE; they have pro-inflammatory actions in human gestational tissues, increasing oxidative stress and the release of cytokines and prostaglandins.

Subscribe to AGER